The data presented in this article are related to the research paper entitled "Increased expression of mitochondrial sodium-coupled ascorbic acid transporter-2 (mitSVCT2) as a central feature in breast cancer", available in Free Radical Biology and Medicine Journal [1] . In this article, we examined the SVCT2 transporter expression in various breast cancer cell lines using RT-PCR and Western blot assays. In addition, we analyzed the subcellular localization of SVCT2 by immunofluorescence colocalization assays DOI of original article: https://doi
Data
Here we report experimental data on SVCT2 transporter expression and localization in human cancer cell lines and tissues. Analysis of SVCT2 expression by RT-PCR and Western blot in four breast cancer cell lines are shown (Fig. 1) . Immunofluorescence colocalization assays for SVCT2 with various organelle markers in the breast cancer cells MCF-7, MDA-231 and MDA-468 revealed mitochondrial localization of SVCT2 (Fig. 2) . This was confirmed with cellular fractionation experiments followed by Western blot for various subcellular fractions (Fig. 3) . We finally analyzed the SVCT2 expression in the Human Protein Atlas, a public database containing a tissue-based map of the human proteome. Examination of numerous tumor samples of different origins (Fig. 4A-U 
Data accessibility
Data is provided in this article.
Value of the data
This research analyzes the expression and subcellular localization of SVCT2 transporter in human cancer cells. Data from this work describe the mitochondrial localization of SVCT2 transporter in breast cancer cell lines. Analysis of numerous tissue microarrays contained in The Human Protein Atlas reveal the intracellular expression of SVCT2 in different cancer tissues. These data are relevant in cancer biology research, especially for the understanding of vitamin C mitochondrial role and its use in therapeutic procedures for human cancer.
SVCT2 immunoreactivity (Fig. 4V ), in contrast with similar samples stained with anti-GLUT1 indicating a plasma membrane staining pattern (Fig. 4W ).
Experimental design, materials and methods

Cell culture
Breast adenocarcinoma cell lines ZR-75, MCF-7, MDA-231 and MDA-468 were grown in DMEM:F12 (1:1) medium. Colon carcinoma cell line CaCo-2 was grown in DMEM medium. Embryonic kidney cell line HEK-293 was grown in DMEM-high glucose medium. All media were supplemented with 10% fetal bovine serum, 1% nonessential amino acids, 1% L-glutamine, penicillin/streptomycin (100 U/ml) and fungizone.
RT-PCR analysis
PCR experiments were performed using the protocol described in Ref. [2] . Briefly, total RNA was extracted from different cell lines using an RNeasy mini kit (Qiagen). cDNA was synthesized with the AffinityScript Multi-Temp RT (Agilent) plus oligo(dT) and random primers. PCR reaction mixture included specific primers for SVCT2 (or Actin) amplification, Taq 2 Master Mix (New England BioLabs) and 100 ng of cDNA. Amplification products were examined by electrophoresis on 1.5% agarose gels and visualized by ethidium bromide staining.
Western blot analysis
Immunoblotting experiments were performed using the protocol described in Ref. [1] . Briefly, total extracts were prepared from different cell lines, quantified, separated by SDS-PAGE and transferred to PVDF membranes. Detection was performed using anti-SVCT2 and anti-GAPDH primary antibodies (Santa Cruz Biotechnology, Inc) followed by Alexa 680 and Alexa 790 secondary antibodies (Jackson Immunoresearch). Membranes were scanned and analyzed with an Odyssey CLx Imaging system (LI-COR Biosiences).
Immunolocalization
Immunofluorescence experiments were performed using the protocol described in Ref. [1] . Briefly, cells were fixed with paraformaldehyde, permeabilized with Triton X-100, blocked with bovine serum albumin, incubated with primary antibodies and incubated with secondary antibodies, before observation by confocal microscopy. The following primary antibodies were used: anti-SVCT2 and anti-RCAS1 (golgi protein) from Santa Cruz Biotechnology, Inc.; anti-COXIV (inner mitochondrial membrane), anti-LAMP2 (lysosome), anti-PDI (endoplasmic reticulum membrane) and anti-GLUT1 from Abcam, Inc. Three different secondary antibodies were used: fluorescein-labeled anti-mouse IgG and Cy3-labeled anti goat-IgG from Jackson Immunoresearch; fluorescein-labeled anti-rabbit IgG from Dako. Samples were observed using an Olympus IX81 fluorescence microscope with a DSU (Disk Scanning Unit) spinning disk confocal system and images were obtained by a HAMAMATSU ORCA-R2 camera controlled by Olympus Xcellence R software. After deconvolution, images were subjected to Pearson colocalization analysis. Statistical correlation of the colocalization index among the different organelle markers was established by one-way Anova, followed by Tukey test for multiple comparison.
Mitochondrial isolation
Cellular fractionation and mitochondria purification were performed using the protocol described in Ref. [1] . Briefly, mitochondria were isolated from different cell lines by differential centrifugation with all steps carried out at 4 C [3] . The final pellet containing mitochondria and different fractions obtained (T: total homogenate; N: nuclear fraction; C: cytoplasmic fraction; R: endoplasmic reticulum) were separated by SDS-PAGE, transferred to PVDF membranes and immunodetected with anti-SVCT2 and anti-COXIV antibodies.
